Abstract
Introduction
Selective laser trabeculoplasty (SLT) and minimally invasive glaucoma surgery (MIGS) are increasingly used options for mild-to-moderate open-angle glaucoma (OAG) care. While most MIGS devices are indicated for use in combination with cataract surgery only, with phacoemulsification playing a role in lowering IOP, newer technologies can also be used as standalone glaucoma surgery.
Methods
This systematic literature review (SLR) aimed to assess the clinical, economic, and humanistic outcomes of MIGS and SLT for the treatment of OAG and was conducted according to PRISMA guidelines. Studies that assessed MIGS or SLT in at least one treatment arm versus any other glaucoma treatment in adults with mild-to-moderate OAG were included. Clinical, humanistic (health-related quality of life [HRQoL] and patient burden), and economic data were extracted, and the methodological quality of included studies was evaluated.
Results
A total of 2720 articles were screened, and 81 publications were included. Fifty-eight reported clinical outcomes. The majority assessed iStent or iStent inject (n=41), followed by OMNI (n=9), gonioscopy-assisted transluminal trabeculotomy (GATT) or the Kahook Dual Blade (KDB) (n=7), Hydrus (n=6), SLT (n=5), Xen Gel Stent (n=2), PreserFlo (n=1), and iTrack (n=1). IOP reduction was observed across prospective studies, varying from −31% to −13.7% at month 6 and from −39% to −11.4% at year 1 versus baseline. Most adverse events were transient and non-serious. Limited humanistic and economic data were identified.
Conclusion
Given their established efficacy and safety, there is a rationale for wider use of MIGS in mild-to-moderate OAG. Of the MIGS devices, iStent and OMNI have the largest clinical evidence base supporting their sustained effectiveness.
Acknowledgments
The research was funded by Sight Sciences.
Disclosure
Louis Cantor, Dan Lindfield, and Dan Nguyen have received honoraria from Sight Sciences. Louis Cantor also reports consulting fees from Zeiss Meditec, Santen, Elios, and Avellino over the past two years and grants from Allergan, outside the submitted work. Francesca Torelli, Carolyn Steeds, Anna W Świder, and Federico Ghinelli are affiliated with Valid Insight, which is a consulting firm commissioned by Sight Sciences that funded this systematic literature review. Jaime E Dickerson, Jr is an active employee at Sight Sciences. Dan Nguyen has received consulting fees from AbbVie/Allergan, Alcon, Vision Engineering, and Elios. The authors report no other conflicts of interest in this work.